Advanced search
Publication Cover
Modern Rheumatology Volume 25, 2015 - Issue 4
Journal homepage
471
Views
36
CrossRef citations to date
0
Altmetric
Original Articles

Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients

Özge BaşaranDepartment of Pediatric Rheumatology, Ankara, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, TurkeyCorrespondence[email protected]
,
Nermin UncuDepartment of Pediatric Rheumatology and Nephrology, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, Turkey
,
Banu Acar ÇelikelDepartment of Pediatric Rheumatology and Nephrology, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, Turkey
,
Aysel TaktakDepartment of Pediatric Nephrology, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, Turkey
,
Gökçe GürDepartment of Pediatric Nephrology, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, Turkey
&
Nilgun CakarDepartment of Pediatric Rheumatology and Nephrology, Child Health, Hematology and Oncology Education and Research Hospital, Ankara, Turkey
Pages 621-624 | Received 12 Sep 2014, Accepted 11 Nov 2014, Published online: 22 Dec 2014

References

  • Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119(2):e474–83.
  • Lidar M, Yonath H, Shechter N, Sikron F, Sadetzki S, Langevitz P, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72–6.
  • Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33(4):273–82.
  • Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–71.
  • Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med. 2009;360(23):2467–70.
  • Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever. Inflammation. 2014 Aug 20. [Epub ahead of print].
  • Ozçakar ZB, Yalçınkaya F, Cakar N, Acar B, Bilgiç AE, Uncu N, et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF. Eur J Pediatr. 2011;170(8):1055–7.
  • Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, Langevitz P. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998; 75(2):216–9.
  • Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol. 2012;167(3):382–90.
  • Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–84.
  • Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167(6):695–6.
  • Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008;75(4): 504–5.
  • Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–8.
  • Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011;70(7):1347–8.
  • Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. Am J Med Sci. 2013;346(2):137–41.
  • Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology. 2012;51(6):1041.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.